Last reviewed · How we verify

Asbjørn Mohr Drewes — Portfolio Competitive Intelligence Brief

Asbjørn Mohr Drewes pipeline: 1 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Opium tincture Opium tincture marketed Opioid analgesic Mu opioid receptor (primary); delta and kappa opioid receptors (secondary) Pain management; Gastroenterology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams University · 1 shared drug class
  2. Ajay Wasan, MD, Msc · 1 shared drug class
  3. Alza Corporation, DE, USA · 1 shared drug class
  4. Archimedes Development Ltd · 1 shared drug class
  5. BioDelivery Sciences International · 1 shared drug class
  6. Boston Children's Hospital · 1 shared drug class
  7. Brigham and Women's Hospital · 1 shared drug class
  8. AdventHealth · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Asbjørn Mohr Drewes:

Cite this brief

Drug Landscape (2026). Asbjørn Mohr Drewes — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/asbj-rn-mohr-drewes. Accessed 2026-05-16.

Related